DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Free Report) major shareholder Koch Thomas Von bought 1,200,000 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The shares were purchased at an average price of $2.50 per share, for a total transaction of $3,000,000.00. Following the transaction, the insider now owns 5,526,435 shares of the company’s stock, valued at approximately $13,816,087.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
DiaMedica Therapeutics Price Performance
NASDAQ:DMAC opened at $2.95 on Tuesday. The company has a market cap of $111.99 million, a P/E ratio of -5.27 and a beta of 1.74. The firm’s 50 day moving average is $2.78 and its two-hundred day moving average is $2.82. DiaMedica Therapeutics Inc. has a fifty-two week low of $1.94 and a fifty-two week high of $4.45.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. Research analysts forecast that DiaMedica Therapeutics Inc. will post -0.67 earnings per share for the current fiscal year.
Hedge Funds Weigh In On DiaMedica Therapeutics
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the company. Oppenheimer restated an “outperform” rating and set a $6.00 price objective (down previously from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st. Craig Hallum initiated coverage on shares of DiaMedica Therapeutics in a research note on Wednesday, April 24th. They set a “buy” rating and a $8.00 price objective for the company.
Check Out Our Latest Analysis on DiaMedica Therapeutics
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Recommended Stories
- Five stocks we like better than DiaMedica Therapeutics
- What Investors Need to Know About Upcoming IPOs
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Capture the Benefits of Dividend Increases
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.